Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Background This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.Methods We conducted a test-negative case-control study. We included medically attended episodes and hosp...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2310807 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141419460231168 |
|---|---|
| author | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Shingo Masuda Ryosuke Osawa Naoto Hosokawa Kei Nakashima Hiroshi Kamura Haruki Imura Hiroki Inoue Suguru Matsuzaka Yukihiro Sugimoto Osamu Kuwamitsu Iori Motohashi Toru Morikawa Rentaro Oda Yuiko Hoshina Takashi Matono Osamu Teshigahara Eiichiro Sando Sadaharu Asami Satoshi Kudo Noboru Akizuki Yoshikazu Muto Tomoichiro Hayakawa Tomoo Kishaba Yasuji Ohara Yoshinao Kubo Motoi Suzuki Konosuke Morimoto |
| author_facet | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Shingo Masuda Ryosuke Osawa Naoto Hosokawa Kei Nakashima Hiroshi Kamura Haruki Imura Hiroki Inoue Suguru Matsuzaka Yukihiro Sugimoto Osamu Kuwamitsu Iori Motohashi Toru Morikawa Rentaro Oda Yuiko Hoshina Takashi Matono Osamu Teshigahara Eiichiro Sando Sadaharu Asami Satoshi Kudo Noboru Akizuki Yoshikazu Muto Tomoichiro Hayakawa Tomoo Kishaba Yasuji Ohara Yoshinao Kubo Motoi Suzuki Konosuke Morimoto |
| author_sort | Haruka Maeda |
| collection | DOAJ |
| description | Background This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.Methods We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged [Formula: see text]16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression.Results For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination at > 180 days was 26.1% (95% CI: 10.6–38.8%); VE of the first booster was 58.5% (48.4–66.7%) at [Formula: see text]90 days, decreasing to 41.1% (29.5–50.8%) at 91 to 180 days. For individuals aged [Formula: see text]60, VE of the first booster was 42.8% (1.7–66.7%) at [Formula: see text]90 days, dropping to 15.4% (−25.9–43.2%) at 91 to 180 days, and then increasing to 44.0% (16.4–62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2–86.7%) at [Formula: see text]90 days and 55.9% (23.4–74.6%) afterward.Conclusion mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan. |
| format | Article |
| id | doaj-art-f0d9d7b4ce4c4d27992396f58f909022 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-f0d9d7b4ce4c4d27992396f58f9090222024-12-04T09:49:47ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123121322510.1080/14760584.2024.2310807Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)Haruka Maeda0Nobuo Saito1Ataru Igarashi2Masayuki Ishida3Mayumi Terada4Shingo Masuda5Ryosuke Osawa6Naoto Hosokawa7Kei Nakashima8Hiroshi Kamura9Haruki Imura10Hiroki Inoue11Suguru Matsuzaka12Yukihiro Sugimoto13Osamu Kuwamitsu14Iori Motohashi15Toru Morikawa16Rentaro Oda17Yuiko Hoshina18Takashi Matono19Osamu Teshigahara20Eiichiro Sando21Sadaharu Asami22Satoshi Kudo23Noboru Akizuki24Yoshikazu Muto25Tomoichiro Hayakawa26Tomoo Kishaba27Yasuji Ohara28Yoshinao Kubo29Motoi Suzuki30Konosuke Morimoto31Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, JapanKenya Research Station, Institute of Tropical Medicine, Nagasaki University, Nagasaki, JapanSchool of Data Science, Yokohama City University School of Medicine, Kanagawa, JapanDepartment of Infectious Disease Medicine, Chikamori Hospital, Kochi, JapanDepartment of Internal Medicine, Nijigaoka Hospital, Nagasaki, JapanDepartment of Infectious Diseases, Nagasaki University Hospital, Nagasaki, JapanDepartment of Infectious Diseases, Kameda Medical Center, Chiba, JapanDepartment of Infectious Diseases, Kameda Medical Center, Chiba, JapanDepartment of Pulmonology, Kameda Medical Center, Chiba, JapanLoco Clinic Nakameguro, Tokyo, JapanDepartment of Infectious Disease Medicine, Rakuwakai Otowa Hospital, Kyoto, JapanDepartment of Infectious Disease Medicine, Rakuwakai Otowa Hospital, Kyoto, JapanDepartment of General Medicine, Fukuoka Seishukai Hospital, Fukuoka, JapanDepartment of Respiratory Medicine, Fukuoka Seishukai Hospital, Fukuoka, JapanGohongi Clinic, Tokyo, JapanDepartment of General Internal Medicine, Kawasaki Municipal Tama Hospital, Kawasaki, JapanDepartment of General Medicine, Nara City Hospital, Nara, JapanDepartment of Infectious Diseases, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, JapanDepartment of Infectious Diseases, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, JapanDepartment of Infectious Diseases, Aso Iizuka Hospital, Fukuoka, JapanMizuho Street Clinic, Aichi, JapanDepartment of General Internal Medicine and Clinical Infectious Diseases, Kita-Fukushima Medical Center, Date, JapanDepartment of Cardiology, Musashino Tokushukai Hospital, Tokyo, JapanDepartment of Nursing, Musashino Tokushukai Hospital, Tokyo, JapanDepartment of Emergency Medicine, Musashino Tokushukai Hospital, Tokyo, JapanDepartment of Infectious Diseases, Tosei General Hospital, Seto, JapanHayakawa Internal Medicine Clinic, Fukuoka, JapanDepartment of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, JapanJin Sakura Clinic, Nagoya, JapanDepartment of Clinical Tropical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanInfectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, JapanDepartment of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, JapanBackground This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.Methods We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged [Formula: see text]16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression.Results For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination at > 180 days was 26.1% (95% CI: 10.6–38.8%); VE of the first booster was 58.5% (48.4–66.7%) at [Formula: see text]90 days, decreasing to 41.1% (29.5–50.8%) at 91 to 180 days. For individuals aged [Formula: see text]60, VE of the first booster was 42.8% (1.7–66.7%) at [Formula: see text]90 days, dropping to 15.4% (−25.9–43.2%) at 91 to 180 days, and then increasing to 44.0% (16.4–62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2–86.7%) at [Formula: see text]90 days and 55.9% (23.4–74.6%) afterward.Conclusion mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.https://www.tandfonline.com/doi/10.1080/14760584.2024.2310807BA.5COVID-19JapanSARS-CoV-2vaccine effectivenessmonovalent |
| spellingShingle | Haruka Maeda Nobuo Saito Ataru Igarashi Masayuki Ishida Mayumi Terada Shingo Masuda Ryosuke Osawa Naoto Hosokawa Kei Nakashima Hiroshi Kamura Haruki Imura Hiroki Inoue Suguru Matsuzaka Yukihiro Sugimoto Osamu Kuwamitsu Iori Motohashi Toru Morikawa Rentaro Oda Yuiko Hoshina Takashi Matono Osamu Teshigahara Eiichiro Sando Sadaharu Asami Satoshi Kudo Noboru Akizuki Yoshikazu Muto Tomoichiro Hayakawa Tomoo Kishaba Yasuji Ohara Yoshinao Kubo Motoi Suzuki Konosuke Morimoto Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) Expert Review of Vaccines BA.5 COVID-19 Japan SARS-CoV-2 vaccine effectiveness monovalent |
| title | Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_full | Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_fullStr | Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_full_unstemmed | Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_short | Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| title_sort | effectiveness of primary series first and second booster vaccination of monovalent mrna covid 19 vaccines against symptomatic sars cov 2 infections and severe diseases during the sars cov 2 omicron ba 5 epidemic in japan vaccine effectiveness real time surveillance for sars cov 2 versus |
| topic | BA.5 COVID-19 Japan SARS-CoV-2 vaccine effectiveness monovalent |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2310807 |
| work_keys_str_mv | AT harukamaeda effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT nobuosaito effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT ataruigarashi effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT masayukiishida effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT mayumiterada effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT shingomasuda effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT ryosukeosawa effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT naotohosokawa effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT keinakashima effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hiroshikamura effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT harukiimura effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hirokiinoue effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT sugurumatsuzaka effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yukihirosugimoto effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT osamukuwamitsu effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT iorimotohashi effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT torumorikawa effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT rentarooda effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yuikohoshina effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT takashimatono effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT osamuteshigahara effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT eiichirosando effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT sadaharuasami effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT satoshikudo effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT noboruakizuki effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yoshikazumuto effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT tomoichirohayakawa effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT tomookishaba effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yasujiohara effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yoshinaokubo effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT motoisuzuki effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT konosukemorimoto effectivenessofprimaryseriesfirstandsecondboostervaccinationofmonovalentmrnacovid19vaccinesagainstsymptomaticsarscov2infectionsandseverediseasesduringthesarscov2omicronba5epidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus |